New possibilities in therapy of ocular inflammation in rheumatic diseases

Close metadata

Recommended articles:

Ocular manifestations of rheumatic diseases. Russian Annals of Ophthalmology. 2024;(4):104-109

Role of doctor-patient communication in rheumatology. Russian Journal of Preventive Medicine. 2025;(4):156-161

This review is devoted to the potential application of genetically engineered biological drugs of different classes in the treatment of main forms of uveitis and other types of non-infectious ocular inflammation in immunoinflammatory rheumatic diseases. The article presents the results of studies demonstrating the influence of interleukin-17 inhibitor secukinumab on the course of uveitis in spondylarthritis, shows the possibilities of treating uveitis in juvenile idiopathic arthritis with inhibitors of interleukin-6, co-stimulation of T-lymphocytes. Inhibition of interleukin-1 is considered an effective method of influencing the ocular inflammation in monogenic autoinflammatory syndromes and Behcet’s disease. Rituximab is considered as an option for immunosuppressive therapy of non-infectious uveitis and scleritis.

Keywords:

uveitis

scleritis

episcleritis

rheumatic diseases

interleukin inhibitors

Authors:

Razumova I.Yu.

Research Institute of Eye Diseases

ORCID: 0000-0003-2982-7418

Godzenko A.A.

Russian Medical Academy of Continuous Professional Education

Received:

06.12.2021

Accepted:

25.03.2022

List of references:

Nasonov EL, Denisov LN, Stanislav ML. Interleukin 17 is a New Target for anti-cytokine Therapy of Immune Inflammatory Rheumatic Diseases. Nauchno-prakticheskaya revmatologiya. 2013;51(5):545-552. (In Russ.).
Ceribelli A, Motta F, Vecellio M, Isailovic N, Ciccia F, Selmi C. Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis. Front Immunol. 2021;12:622770. https://doi.org/10.3389/fimmu.2021.622770
Guedes MC, Borrego LM, Proença RD. Roles of interleukin 17 in uveitis. Indian J Ophthalmol. 2016;64(9):628-634. https://doi.org/10.4103/0301-4738.194339
Hueber W, Patel DD, Dryia T, Wright A, Koroleva I, Bruin G, Antoni Ch, Draelos Z, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2(52):52ra72. https://doi.org/10.1126/scitranslmed.3001107
Letko E, Yen S, Foster GS, Pleyer U, Brigell M, Grosskreitz CL. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive. J Ophthalmol. 2015;122(5):939-948. https://doi.org/1016/j.ophtha 2014.12.033
Braun J, Baraliakos X, Deodhar A, Baeten D, Stepper J, Emery P, Readie A, Martin R, Mpofu S, Richards H. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070-1077. https://doi.org/10.1136/annrheumdis-2016-209730
Deodhar A, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, Gupta AD, Martin R, Safi Jr J, Porter B, Shete A, Rosenbaum JT. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR Open Rheumatol. 2020;2(5):294-299. https://doi.org/10.1002/acr2.11139
Lindström U, Bengtsson K, Olofsson T, Di Giuseppe D, Glintborg B, Forsblad-d’Elia H, Jacobsson LTH, Askling J. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter? Ann Rheum Dis. 2021;80(11):1445-1452. https://doi.org/10.1136/annrheumdis-2021-220420
Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22:155-157. https://doi.org/10.3109/09273948 2013 866254
Tappeiner C, Mesquida M, Adan A, Anton J, Romanan AV, Carreno E, Mackensen F, Kotaniemi K, deBoer JH, Bou R, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43:2183-2188. https://doi.org/103899/j.rheum 160231
Calvo-Río V, Santos-Gómez M, Calvo I, González-Fernández MI, López-Montesinos B, Mesquida M, Adán A, Hernández MV, Maíz O, Atanes A, Bravo B, Modesto C, Díaz-Cordovés G, Palmou-Fontana N, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheum. 2017;69(3): 668-675. https://doi.org/10.1002/art.39940
Bunchuk NV. Gigantokletochnyy arteriit i revmaticheskaya polimialgiya [On giant cell arteritis and rheumatic polymyalgia]. M.: Erus; 1992;156. (In Russ.).
Salvarani C, Cantini F, Boiardi L, Hunder G. Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol. 2003; 21(6 suppl 32):23-28.
Pulsatelli L, Boiardi L, Assirelli E, Pazzola G, Muratore F, Addimanda O, Dolzani B, Vorsan F, Casali M, et al. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol. 2017;35 suppl 103(1):102-110.
Beketova TV, Ushakova MA, Nikishina NYu, Khelkovskaya-Sergeeva AN, Nikolaeva EN, Sazhina EG, Novoselova TM, Nasonov EL. Experience with tocilizumab, an interleukin 6 inhibitor, used for the treatment of giant cell arteritis with severe comorbidity. Nauchno-prakticheskaya revmatologiya. 2018;56(2):228-234. (In Russ.). https://doi.org/10/14412/1995-4484-2018-228-234
Stone JH, Tuckwell K, Dimonaco S, Klerman M, Aringer M, Blockmans D, Brouver E, Cid MC, Dasgupta B, Rech S, Salvaroni C, Spiera RF, Unizom SH, Collinson N. Efficacy and safety of tocilizumab in patients with giant cell arteritis: Primary and secondary outcomes from a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2016;68(10):abstr.911.
Regola F, Cerudelli E, Bosio G, Andreoli L, Tincani A, Franceschini F, Toniati P. Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients. Rheumatol Adv Pract. 2020; 4(2):rkaa017. eCollection 2020. https://doi.org/10.1093/rap/rkaa017
Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016;12(1):14-24. https://doi.org/10.1038/nrrheum 2016.166
Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P. Scleritis: Immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res. 2013;16(88):153-157. https://doi.org/10.1016/jpreteyeres 2013.02.004
Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O. Use of gevokizumab in patients with Behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and openlabel extension study. Ocul Immunol Inflamm. 2018;25:1-11. https://doi.org/10.1080/09273948.2017.1421233
Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191-197. Epub 2016 Dec 16. https://doi.org/10.1007/s10067-016-3506-4
Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, Obiyor D, Nussenblatt RB, Sen HN. Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. Am J Ophthalmol. 2016;172:104-110. https://doi.org/10.1016/j.ajo.2016.09.017
Muckle TJ, Wellsm. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med. 1962;31:235-248.
Cekic S, Yalcinbayir O, Kilic SS. Ocular Involvement in Muckle-Wells Syndrome. Ocul Immunol Inflamm. 2020;28(1):70-78. Epub 2018. https://doi.org/10.1080/09273948.2018.1552305
Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin IB, Kim HJ, Brewet C, Zalewwsky C, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6):581-592. https://doi.org/10.1056/NEJM oa.055.137/
Lepore L, Paloni G, Caorsi R, Alessio M, Rigante D, Ruperto N, Cattalini M, Tommasini A, Zulian F, Ventura A, Martini A, Gatorno M. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr. 2010;157(2):310-315. https://doi.org/10.1016/j.jpeds 2010.02.040
Yokota S, Imagawa T, Nishikomori R, Takada H, Abrams K, Lheritier K, Heike T, Hara T. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. Clin Exp Rheumatol. 2017;108(6):19-26.
Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095-2102. https://doi.org/10.1036/ard 2011.152-728
Kim L, Li A, Angeles-Han S, Yeh S, Shautha JS. Update on the management of uveitis in children: an overview for the clinician. Exp Rev Ophthalmol. 2019;14(4-5):211-218. https://doi.org/10.1080/17469899.2019.1663731
Birolo C, Zannin ME, Arsenyeva S, Cimaz R, Miserocchi E, Dubko M, Deslandre CJ, Falcini F, Alessio M, La Torre F, Denisova E, Martini G, Nikishina I, Zulian F. Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis. J Rheumatol. 2016;43(11):2068-2073. Epub 2016 Sep 15. https://doi.org/10.3899/jrheum.151389
Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013;72(2):ii2-i34. https://doi.org/10.1136/annrheumdis-2013-203348
Ng CC, Sy A, Cunningham ET Jr. Rituximab for non-infectious Uveitis and Scleritis. J Ophthalm Inflamm Infect. 2021;11(1):23. https://doi.org/10.1186/s12348-021-00252-4
Ng CC, Sy A, Cunningham ET Jr. Rituximab for treatment of non- infectious and non-malignant orbital inflammatory disease. J Ophthalm Inflamm Infect. 2021;11(1):24. https://doi.org/10.1186/s12348-021-00253-3
Ciccia F, Guggino G, Rizzo A, Alessandro R, Carubbi F, Giardina A, et al. Rituximab Modulates IL-17 Expression in the Salivary Glands of Patients with Primary Sjögren’s Syndrome. Rheumatology (Oxford). 2014;53(7):1313-1320. https://doi.org/10.1093/rheumatology/keu004
Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot J-M, Perdriger A, Puéchal X, Guern VL, Sibilia J, Gottenberg J-E, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Pers JO, Nowak E, Saraux A. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233-242. https://doi.org/10.7326/M13-1085
Meijer JM, Meiners PM, Vissink A, Spijkervet FKL, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CGM, Bootsma H. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960-968. https://doi.org/10.1002/art.27314
Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, Chams-Davatchi C, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246-252. https://doi.org/10.1111/j.1756-185X.2010.01546.x
Hickman RA, Denniston AK, Yee CS, Toescu V, Murray PI, Gordon C. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy. Lupus. 2010;19(3):327-329. https://doi.org/10.1177/0961203309347332
Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2018;13:53-55. https://doi.org/10.1016/j.ajoc.2018.12.001
Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847-851. https://doi.org/10.1007/s10067-019-04875-w

Close metadata